Articles tagged "Antilymphocyte antibodies"

2020 American Transplant Congress
Carfilzomib-Based Desensitization: Effects on HLA, Non-HLA, Auto, and Antiviral Antibodies
S. Tremblay¹, E. Portwood¹, A. R. Shields², R. R. Alloway¹, P. A. Brailey¹, E. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²U Cincinnati, Christ Hospital, Cincinnati, OH
*Purpose: An important question in plasma cell (PC) therapies is the specificity of therapy for PC populations. It is known that plasmablast populations are exquisitely…
2020 American Transplant Congress
Thymoglobulin Dose and Incidence of Biopsy Proven Acute Rejections in the Early Post Transplant Period
K. Shimko, K. Schonder, D. Jorgensen, K. Kalra, A. Cherukuri, R. Mehta, I. Melgarejo, P. Sood, S. Hariharan, R. Mehta
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Optimal dosing of thymoglobulin (ATG) for induction has not been well defined. Our protocol aims for 5-6mg/kg cumulative dose divided over 4 doses. However,…
2020 American Transplant Congress
Short Term Outcomes in Kidney Transplant Patients Receiving De Novo Belatacept with Anti-Thymocyte Globulin Induction
B. Carlson, P. Cabrera, T. Harrison, K. Tejani, A. Centeno
Pharmacy, Jackson Memorial Hospital, Miami, FL
*Purpose: Mainstay immunosuppressive therapy after kidney transplant is a calcineurin inhibitor (CNI) based regimen. Nephrotoxicity is a common adverse effect of CNIs which can lead…
2020 American Transplant Congress
Outcomes of Induction with T Lymphocyte-Depleting and IL-2 Receptor Blocking (IL-2RB) Antibodies in the Non-Broadly Sensitized Adult Deceased-Donor Kidney Transplant Recipients: Analysis in the Context of the CPRA Allocation System
A. H. Santos Jr¹, Y. Li², K. Alquadan¹, M. Leghrouz¹, X. Wen³
¹Div. of Nephrology, Univ. of Florida, Gainesville, FL, ²Univ. of Florida, Gainesville, FL, ³Univ. of Rhode Island, Kingston, RI
*Purpose: We studied outcomes of induction in non-broadly-sensitized adult deceased-donor kidney transplant recipients(DD-KTRs) in the context of the calculated panel reactive antibody (CPRA) allocation system.*Methods:…
2020 American Transplant Congress
Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients in the Current Era of Immunosuppression
M. Zachariah¹, I. Mallawaarachchi², N. Meeks³, D. Wright¹, R. Minawala¹, V. Liu¹, J. Rolls⁴, S. Hussein⁴, C. Jarrin⁵
¹Wayne State University, Detroit, MI, ²Division of Biostatistics, University of Virginia, Charlottsville, VA, ³Wayne State University School of Medicine, Detroit, MI, ⁴Surgery, Detroit Medical Center, Detroit, MI, ⁵Infectious Disease, Wayne State University, Detroit, MI
*Purpose: It is now common practice in the transplant community to select induction therapy on the basis of perceived immunological risk for acute rejection which…
2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
R. M. Hofmann¹, J. Combs², K. J. Schmidt³, T. Dyckman⁴
¹Nephrology, Renal Associates of West Michigan, Grand Rapids, MI, ²Pharmacy/Transplant, Mercy Health St. Mary's, Grand Rapids, MI, ³Pharmacy, Ferris State University College of Pharmacy, Big Rapids, MI, ⁴Pharmacy, Mercy Health St. Mary's, Grand Rapids, MI
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…
2020 American Transplant Congress
Causal Relationship between Anti-Thymocyte Globulin Induction Therapy and Development of Monomorphic PTLD in Renal Transplant Recipients
K. Soliman¹, H. Ali², T. Fulop¹, A. Osman³, A. Halawa⁴
¹Medicine, Medical University of South Carolina, Charleston, SC, ²Medicine, Royal Stoke, Royal Stoke, United Kingdom, ³Medicine, Cairo University, Cairo, Egypt, ⁴Medicine, University of Liverpool, Liverpool, United Kingdom
*Purpose: The aim of our study is to explore the causality between ATG and different types of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients…
2020 American Transplant Congress
Comparison of Short-Term Outcomes of Induction Therapy with Alemtuzumab versus Rabbit Antithymocyte Globulin in Lung Transplantation
V. Liu, M. W. Soto-Arenall, A. Patel
Pharmacy, Mayo Clinic, Jacksonville, FL
*Purpose: To identify the short-term efficacy and safety outcomes of alemtuzumab (C1H) versus rabbit antithymocyte globulin (rATG) in lung transplant patients. The objectives are to…
2020 American Transplant Congress
A Recombinant, Fully Human ATG Polyclonal Antibody Drug Drives Immune Cell Depletion in a Model of Graft-versus-Host Disease
S. M. Keating, A. S. Adler, R. A. Mizrahi, J. Leong, M. A. Asensio, Y. W. Lim, A. R. Niedecken, Y. Chiang, R. Leong, D. S. Johnson
Immunology, GigaGen, South San Francisco, CA
*Purpose: Anti-thymocyte globulin (ATGs) are polyclonal antibody products that target and deplete T cells for immunosuppression in transplantation (prophylaxis of rejection). Since ATGs are derived…
2020 American Transplant Congress
Depletional Profiles of Human and Rhesus Specific Anti-Thymocyte Globulins in Rhesus Macaques
B. I. Shaw¹, R. Schmitz¹, D. M. Magnani², F. Leopardi¹, A. D. Kirk¹
¹Surgery, Duke University, Durham, NC, ²Medicine, MassBiologics of the University of Massachusetts Medical School, Boston, MA
*Purpose: Rabbit anti-human ATG (rATG; Thymoglobulin®) is the most commonly used formulation for depletional induction therapy in the United States. However, given that it is…

1
2
3
…
7
Next Page »